文献速递心脑血管急症

多支冠状动脉病变延长双联抗血小板治疗

Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
PubMed 文献 · N Engl J Med · 2026-01-01
一句话结论多支冠状动脉病变患者药物洗脱支架植入后12个月无事件,再延长氯吡格雷联合阿司匹林双联抗血小板治疗12个月,较阿司匹林单药降低缺血事件风险且未增加出血。

该开放标签随机试验在中国97个中心纳入8250例多支冠状动脉病变患者,这些患者药物洗脱支架植入后接受双联抗血小板治疗12个月无主要缺血或出血事件,随机分为延长双联抗血小板治疗(氯吡格雷联合阿司匹林)12个月组或阿司匹林单药组。中位随访34.3个月,双联治疗组主要疗效终点(心血管死亡、非致死性心肌梗死或非致死性卒中)36个月累积发生率5.8%,阿司匹林单药组6.8%(HR 0.82,95%CI 0.69-0.98,P=0.03)。临床相关或大出血两组分别为1.4%和1.5%(HR 0.89,95%CI 0.61-1.30,P=0.54)。

要点

  • 多支冠状动脉病变患者药物洗脱支架植入后双联抗血小板治疗12个月无事件,延长氯吡格雷联合阿司匹林12个月较阿司匹林单药降低主要疗效终点事件(36个月累积发生率5.8% vs 6.8%,HR 0.82,95%CI 0.69-0.98,P=0.03)。
  • 延长双联抗血小板治疗未增加临床相关或大出血(BARC≥2型)风险(36个月累积发生率1.4% vs 1.5%,HR 0.89,95%CI 0.61-1.30,P=0.54)。
  • 研究纳入18至75岁多支冠状动脉病变患者,药物洗脱支架植入后双联抗血小板治疗12个月期间无主要缺血或出血事件。
  • 中位随访34.3个月,主要疗效终点为心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点。

适用人群与场景

  • 18至75岁多支冠状动脉病变患者,药物洗脱支架植入后接受双联抗血小板治疗12个月,期间无主要缺血或出血事件。

处置流程与药物剂量

  • 符合条件的患者随机接受延长12个月双联抗血小板治疗(氯吡格雷联合阿司匹林)或阿司匹林单药治疗。

研究设计与关键结果

  • 开放标签随机试验,中国97个中心,8250例患者随机1:1接受延长双联抗血小板治疗(4125例)或阿司匹林单药(4125例),中位随访34.3个月。
  • 主要疗效终点(心血管死亡、非致死性心肌梗死或非致死性卒中)双联治疗组222例 vs 阿司匹林单药组266例(36个月Kaplan-Meier累积发生率5.8% vs 6.8%;HR 0.82;95%CI 0.69-0.98;P=0.03)。
  • 主要安全终点临床相关或大出血(BARC≥2型)双联治疗组51例 vs 阿司匹林单药组57例(36个月Kaplan-Meier累积发生率1.4% vs 1.5%;HR 0.89;95%CI 0.61-1.30;P=0.54)。

证据类型、等级与局限

  • 证据类型:开放标签随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于多支冠状动脉病变患者,药物洗脱支架植入后双联抗血小板治疗12个月无主要缺血或出血事件者,作者认为延长氯吡格雷联合阿司匹林治疗12个月较阿司匹林单药可降低心血管死亡、非致死性心肌梗死或非致死性卒中风险,且未增加出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with multivessel coronary artery disease often receive 12 months of dual antiplatelet therapy (DAPT) after stenting to reduce the risk of ischemic events. Whether extending DAPT beyond 12 months in event-free patients with multivessel disease provides a benefit is uncertain.

METHODS: We conducted an open-label, randomized trial at 97 centers in China. Patients 18 to 75 years of age with multivessel coronary artery disease who had no major ischemic or bleeding events while receiving DAPT for 12 months after implantation of a drug-eluting stent were randomly assigned in a 1:1 ratio to receive an additional 12 months of DAPT (clopidogrel plus aspirin) or aspirin monotherapy. The primary efficacy end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary safety end point was clinically relevant or major bleeding (i.e., a bleeding event of Bleeding Academic Research Consortium [BARC] type ≥2; BARC types range from 0 to 5, with higher values indicating greater severity of bleeding).

RESULTS: A total of 8250 patients were randomly assigned to receive extended DAPT (4125 patients) or aspirin monotherapy (4125 patients). The median follow-up was 34.3 months. A primary efficacy end-point event occurred in 222 patients in the DAPT group and in 266 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 5.8% vs. 6.8%; hazard ratio, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03). Clinically relevant or major bleeding occurred in 51 patients in the DAPT group and in 57 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 1.4% vs. 1.5%; hazard ratio, 0.89; 95% CI, 0.61 to 1.30; P = 0.54).

CONCLUSIONS: Among patients with multivessel coronary artery disease who were in stable condition 12 months after implantation of a drug-eluting stent, extending DAPT with clopidogrel and aspirin for an additional 12 months led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than continuing aspirin alone, without an increased risk of bleeding. (Funded by the National Natural Science Foundation of China and others; DAPT-MVD ClinicalTrials.gov number, NCT04624854.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Tian J, Wang Z, Wang Y, et al. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. 2026. PMID: 42456136. doi:10.1056/NEJMoa2517588

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。